Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Impact of maternal SARS-CoV-2 infection on neonatal immunology

Although extensive studies have been carried out on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and evidence exists that pregnant women are at elevated risk of severe COVID-19, the impact of maternal infection on the fetus is not clear. The majority of pregnant women infected with SARS-CoV-2 are asymptomatic or experience mild symptoms.

7 Jun 2021

Standardizable assay detects T cell responses to SARS-CoV-2 infection

Researchers in the UK have developed a high-throughput standardizable assay that accurately detects T cell responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

6 Jun 2021

Missing antibody molecule may predict disease severity in secondary dengue infection

A first encounter with the dengue virus typically causes very mild symptoms; however, a subsequent infection is a different story.

5 Jun 2021

Gene offers some level of protection from severe Covid

The first evidence of a genetic link explaining why some people who catch Covid-19 don't become sick has been discovered.

5 Jun 2021

Maternal SARS-CoV-2 infection imprints immune response in the newborn

A new bioRxiv* preprint reports the immunological footprint in the newborn left by maternal infection with SARS-CoV-2 during pregnancy.

4 Jun 2021

SARS-CoV-2 evades neutralizing antibodies and rapidly spreads by cell fusion, finds study

In a new study by researchers in the UK, Germany and South Africa, this process is visualized using time-lapse microscopy of a human cell lung line, demonstrating that SARS-CoV-2 can induce cell-to-cell fusion within 6 hours post-infection. Further, the application of neutralizing monoclonal antibodies or convalescent plasma was unable to prevent the spread of the virus by this mechanism, suggesting that removing SARS-CoV-2 from cells permissive of cell membrane fusion could be more difficult than other types of cell.

4 Jun 2021

Methotrexate users fail to achieve adequate immune response to mRNA COVID-19 vaccines

Up to a third of patients taking methotrexate – a common treatment for immune mediated inflammatory conditions such as rheumatoid arthritis and psoriasis/psoriatic arthritis – failed to achieve an adequate immune response to mRNA COVID-19 vaccines in a small study accepted for publication in the journal Annals of the Rheumatic Diseases.

4 Jun 2021

Waters launches new RUO LC-MS test method to advance infectious disease research

Waters Corporation today introduced a new RUO LC-MS test method to advance critical infectious disease research.

4 Jun 2021

New strategy for developing universal flu vaccine

A new study from the University of Chicago and Scripps Research Institute shows that during the last great pandemic--2009's H1N1 influenza pandemic--people developed strong, effective immune responses to stable, conserved parts of the virus.

4 Jun 2021

Study: Nasal therapy is more effective than commonly used IgG antibodies at neutralizing COVID-19 virus

A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.

4 Jun 2021

People who received Pfizer-Biontech vaccine have lower antibody levels targeting the delta variant

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.

4 Jun 2021

Mast cell activation may underlie inflammation in severe COVID-19

A new preprint research paper posted to the medRxiv* server points to mast cells as major culprits in the etiology of severe and critical COVID-19. This could suggest suitable therapeutic and preventive interventions to reduce the morbidity and mortality of this viral illness.

3 Jun 2021

Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants

Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.

3 Jun 2021

Antibody treatment reactivates the immune defense in patients with advanced-stage cancer

Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer.

3 Jun 2021

Researchers develop rapid antibody screening method for novel COVID-19 therapeutics development

New research undertaken by researchers in the USA describes two parallel but distinct in vivo approaches for the accelerated discovery of antibodies targeting SARS-CoV-2 spike protein.

3 Jun 2021

Study compares Pfizer and Moderna mRNA vaccine-elicited response to SARS-CoV-2 variants

A new study has been published on the bioRxiv preprint server which focuses on the correlation between the vaccine-triggered Immunoglobulin G (IgG) levels and neutralization titers against SARS-CoV-2 variants. Further, neutralization activities against the variants (B.1.1.7, B.1.525, and B.1.351), using Pfizer or Moderna vaccine, sera were assessed.

3 Jun 2021

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.

3 Jun 2021

New study will help design better antibodies for potential treatments

Scientists are harnessing hard X-rays in the fight against cancer. A team of researchers, in conjunction with the U.S. Department of Energy's (DOE) Argonne National Laboratory, has used ultrabright X-ray light to determine how specific types of antibodies can tell the difference between different forms of a cancer-linked molecule.

3 Jun 2021

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

One-quarter of people who take the drug methotrexate for common immune system disorders -- from rheumatoid arthritis to multiple sclerosis -- mount a weaker immune response to a COVID-19 vaccine, a new study shows.

2 Jun 2021

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

A new bioRxiv* preprint reports on the successful use of a protocol to expand SARS-CoV-2-reactive T-cells a thousand-fold.

2 Jun 2021

Antibody News and Research

Further Reading

Impact of maternal SARS-CoV-2 infection on neonatal immunology

Standardizable assay detects T cell responses to SARS-CoV-2 infection

Missing antibody molecule may predict disease severity in secondary dengue infection

Gene offers some level of protection from severe Covid

Maternal SARS-CoV-2 infection imprints immune response in the newborn

SARS-CoV-2 evades neutralizing antibodies and rapidly spreads by cell fusion, finds study

Methotrexate users fail to achieve adequate immune response to mRNA COVID-19 vaccines

Waters launches new RUO LC-MS test method to advance infectious disease research

New strategy for developing universal flu vaccine

Study: Nasal therapy is more effective than commonly used IgG antibodies at neutralizing COVID-19 virus

People who received Pfizer-Biontech vaccine have lower antibody levels targeting the delta variant

Mast cell activation may underlie inflammation in severe COVID-19

Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants

Antibody treatment reactivates the immune defense in patients with advanced-stage cancer

Researchers develop rapid antibody screening method for novel COVID-19 therapeutics development

Study compares Pfizer and Moderna mRNA vaccine-elicited response to SARS-CoV-2 variants

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

New study will help design better antibodies for potential treatments

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo